Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Must have received: anti-plasma cell-directed therapy

need for additional therapy after at least 1 line of anti-plasma cell-directed therapy

Cannot have received: CAR-T cell therapy

Prior CAR T cell therapy directed at any target

Cannot have received: BCMA-targeting therapy

Prior BCMA-targeting therapy

Cannot have received: T cell engaging therapy

Exception: within the last 6 months

Prior treatment with any approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months